Experiences with
Calquence283 public posts
Want to take advantage of all our features? Just log in!
or
BTK Is the Target That Keeps on Giving: A Review of BTK-Degrader Drug Development, Clinical Data, and Future Directions in CLL
Here's a welcome article that explains all about BTK degraders; the next class of BTK drug after the success of the FDA approved covalent BTKis (acalabrutinib/Calquence, ibrutinib/Imbruvica and zanubrutinib/Brukinsa) and non-covalent BTKi pirtobrutinib/Jaypirca.